Related Experiment Video
Updated: Aug 16, 2026
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Prognosis value of galectin-3 in patients with dilated cardiomyopathy: a meta-analysis
Yan Xiong1,2, Qing Zhang1
1Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Insights
Elevated galectin-3 (gal-3) levels predict major adverse cardiovascular events (MACEs) in dilated cardiomyopathy (DCM) patients. Combining gal-3 with late gadolinium enhancement (LGE) improves MACE prediction, warranting further research.
Area of Science:
- Cardiology
- Biomarkers
- Medical Imaging
Background:
- Dilated cardiomyopathy (DCM) requires accurate prediction of myocardial fibrosis (MF) and major adverse cardiovascular events (MACEs).
- Galectin-3 (gal-3) has emerged as a potential prognostic biomarker in DCM patients.
Purpose of the Study:
- To evaluate the prognostic value of galectin-3 (gal-3) for MACEs in patients with DCM.
- To assess the role of gal-3 in predicting MACEs in conjunction with late gadolinium enhancement (LGE).
Main Methods:
- A systematic literature search was performed across major databases up to August 2023.
- Hazard ratios (HRs) for gal-3 and MACEs in DCM patients and LGE-stratified groups were analyzed.
- Statistical analysis was conducted using STATA SE 14.0 software.
Main Results:
- Seven studies (945 patients) were included.
- Elevated gal-3 levels were associated with increased MACE risk in DCM (HR = 1.10; p=0.008).
- Gal-3 levels were higher in LGE-positive than LGE-negative groups, and their combination improved MACE prediction.
Conclusions:
- Elevated gal-3 is a significant correlate of MACE risk in DCM.
- Gal-3 shows promise as a biomarker for DCM prognosis, especially when combined with LGE.
- Further research is needed to clarify gal-3's predictive and diagnostic utility due to study heterogeneity.
Background:
Accurate prediction and assessment of myocardial fibrosis (MF) and adverse cardiovascular events (MACEs) are crucial in patients with dilated cardiomyopathy (DCM). Several studies indicate that galectin-3 (gal-3) as a promising prognostic predictor in patients with DCM.
Methods:
A comprehensive search was conducted in PubMed, EMBASE, the Cochrane Library, and Web of Science for relevant studies up to August 2023. The hazard ratios (HRs) of gal-3 for MACEs in DCM patients, and for MACEs in LGE(+) versus LGE(-) groups, were evaluated. Statistical analysis was performed using STATA SE 14.0 software.
Results:
Seven studies, encompassing 945 patients, met the eligibility criteria. In DCM patients, abnormally elevated gal-3 levels were indicative of an increased MACEs risk (HR = 1.10, 95% CI [1.00-1.21], I2 = 65.7%, p = 0.008). Compared with the LGE(-) group, the level of gal-3 in LGE(+) group was higher (HR = 1.12, 95% CI [1.05-1.19], I2 = 31.4%, p = 0.233), and the combination of gal-3 and LGE significantly improved the prediction of MACEs. Sensitivity analysis confirmed the robustness of all results.
Conclusions:
This study's findings suggest that elevated gal-3 levels significantly correlate with increased MACE risk in DCM, highlighting its potential as a biomarker. However, significant heterogeneity among studies necessitates further research to ascertain gal-3's predictive and diagnostic value in DCM prognosis, particularly in conjunction with LGE.
Prospero Id:
CRD42023471199.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:26Heart Failure III: Clinical Manifestations